イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - rituximab - solution for infusion - 10mg/1ml

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - rituximab - solution for infusion - 10mg/1ml

カナダ - 英語 - Health Canada

auro pharma inc - ibritumomab tiuxetan - kit - 3.2mg - ibritumomab tiuxetan 3.2mg - radioactive agents

カナダ - 英語 - Health Canada

united therapeutics corporation - dinutuximab - solution - 3.5mg - dinutuximab 3.5mg - antineoplastic agents

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium citrate dihydrate; polysorbate 80; water for injections; sodium chloride - non-hodgkin?s lymphoma tuxella is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma , chronic lymphocytic leukaemia tuxella is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma tuxella is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma , chronic lymphocytic leukaemia tuxella is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rituximab 10 mg/ml - concentrate for infusion - 10 mg/ml - active: rituximab 10 mg/ml excipient: citric acid monohydrate hydrochloric acid polysorbate 80 sodium chloride sodium hydroxide water for injection - latest regulatory activity

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; polysorbate 80; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma ritemvia is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma;

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium citrate dihydrate; polysorbate 80; water for injections; sodium chloride - non-hodgkin?s lymphoma ritemvia is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma;

マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - cetuximab -